ALK and non-small cell lung carcinoma: Furthermore, brigatinib, a potent dual inhibitor of ALK and EGFR with potential CNS penetration, was granted accelerated approval for patients with metastatic ALK-positive NSCLC who are resistant or intolerant to crizotinib by the FDA on April 28, 2017.